Abstract:Histone acetylation modification is governed by the intricate interplay of histone deacetylases (HDACs) and histone acetyltransferases (HATs), where elevated HDAC activity in both neurons and immune cells regulates the expression of genes implicated in pain pathways, promoting neuronal excitability and neuroinflammation, and ultimately, enabling neuropathic pain. Background Neuropathic pain remains a formidable challenge for modern medicine. The first‐line pharmacological therapies exhibit limited efficacy and unfavorable side effect profiles, highlighting an unmet need for effective therapeutic medications. The past decades have witnessed an explosion in efforts to translate epigenetic concepts into pain therapy and shed light on epigenetics as a promising avenue for pain research. Recently, the aberrant activity of histone deacetylase (HDAC) has emerged as a key mechanism contributing to the development and maintenance of neuropathic pain. Aims In this review, we highlight the distinctive role of specific HDAC subtypes in a cell‐specific manner in pain nociception, and outline the recent experimental evidence supporting the therapeutic potential of HDACi in neuropathic pain. Methods We have summarized studies of HDAC in neuropathic pain in Pubmed. Results HDACs, widely distributed in the neuronal and non‐neuronal cells of the dorsal root ganglion and spinal cord, regulate gene expression by deacetylation of histone or non‐histone proteins and involving in increased neuronal excitability and neuroinflammation, thus promoting peripheral and central sensitization. Importantly, pharmacological manipulation of aberrant acetylation using HDAC‐targeted inhibitors (HDACi) has shown promising pain‐relieving properties in various preclinical models of neuropathic pain. Yet, many of which exhibit low‐specificity that may induce off‐target toxicities, underscoring the necessity for the development of isoform‐selective HDACi in pain management. Conclusions Abnormally elevated HDACs promote neuronal excitability and neuroinflammation by epigenetically modulating pivotal gene expression in neuronal and immune cells, contributing to peripheral and central sensitization in the progression of neuropathic pain, and HDACi showed significant efficacy and great potential for alleviating neuropathic pain.

HDAC6 as a potential therapeutic target for peripheral nerve disorders

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease

Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease

A novel insight into neurological disorders through HDAC6 protein–protein interactions

Classical HDACs in the Regulation of Neuroinflammation.

Role of histone deacetylases and their inhibitors in neurological diseases

Aberrant GlyRS-HDAC6 Interaction Linked to Axonal Transport Deficits in Charcot-Marie-Tooth Neuropathy

HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice

Inhibition of HDAC6 Activity in Kidney Diseases: a New Perspective

Identification of Potential Inhibitors of Histone Deacetylase 6 Through Virtual Screening and Molecular Dynamics Simulation Approach: Implications in Neurodegenerative Diseases

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Structure, Functions and Selective Inhibitors of HDAC6

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020)

Role of histone deacetylase 6 in aggresome and neurodegenerative diseases

Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances

HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation

Recent Development of Novel HDAC6 Isoform-Selective Inhibitors.